jnj-39393406
Small moleculeexperimental
Clinical trial activity
7 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2009 (NCT02023255)
Timeline
Indications
Mechanism of action
- Neuronal acetylcholine receptor protein alpha-7 subunitPOSITIVE ALLOSTERIC MODULATOR
CHRNA7 positive allosteric modulator
Chemistry & pharmacology
Loading structure…
SMILES
CN(C)C(=O)CCn1nc(Nc2ccc3c(c2)OC(F)(F)O3)nc1-c1ccncc1- Mol. weight
- 416.39 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545291 ↗
Also known as
- jnj 39393406
- jnj 39393406
- jnj-39393406
- jnj-39393406
- jnj-39393406
- jnj-39393406
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02677207 | Phase 2 | Feb 1, 2016 | JK Organization, Johnson and Johnson |
| NCT02217527 | Phase 2 | Nov 1, 2014 | National Institutes of Health (NIH), University of Pittsburgh |
| NCT02230384 | Phase 2 | Sep 1, 2014 | National Institutes of Health (NIH), University of Pittsburgh, Virginia Commonwealth University |
| NCT01556217 | Phase 1 | Sep 1, 2010 | Johnson and Johnson |
| NCT01137799 | Phase 1 | Aug 1, 2009 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT01986491 | Phase 1 | May 1, 2009 | Johnson and Johnson |
| NCT02023255 | Phase 1 | Jan 1, 2009 | Johnson and Johnson |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 5 | 4 | 2 | 2009 |
| National Institutes of Health (NIH) | Government | 2 | 0 | 1 | 2014 |
| University of Pittsburgh | Academic/Hospital | 2 | 2 | 1 | 2014 |
| Janssen Pharmaceutica NV | For profit | 1 | 0 | 1 | 2009 |
| JK Organization | For profit | 1 | 1 | 1 | 2016 |
| Virginia Commonwealth University | Academic/Hospital | 1 | 0 | 1 | 2014 |
6 organizations
Page 1 / 1